Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Neogene Therapeutics Inc.
Headquarters: New York, NY, United States of America
Website: N/A
Year Founded: 2018
Status: Acquired
BioCentury | Nov 23, 2024
Finance
Latest Jeito bet positions European VC for fourth exit
Mega-round for Alentis spotlights French firm’s investment style
BioCentury | May 22, 2024
Deals
Biogen’s ‘pick and choose’ strategy in immunology leads to $1B HI-Bio takeout
Continuing diversity push under Viehbacher, Biogen obtains two programs spun out from MorphoSys, backed by Arch, Monograph, Jeito and others
BioCentury | Nov 10, 2023
Management Tracks
New CFO, CMO at TreeFrog
Plus: Metagenomi names Borges CSO and Wapnick CFO, and updates from Teva, Century, Assembly and more
BioCentury | Oct 31, 2023
Management Tracks
CSO, CFO changes at Third Harmonic
Plus: MediLink hires Steve Chin as CMO, and updates from ImmPACT,
BioCentury | May 2, 2023
Management Tracks
Azam named CEO at Inspirna
Plus: Day One promotes Blackman to head of R&D, and updates from Esperovax, Ring, Alladapt, Innoviva and more
BioCentury | Feb 22, 2023
Management Tracks
Gandhi named CMO at NextPoint
Plus: Mathias to become CEO at Oxford, and updates from Novartis and Shoreline
BioCentury | Dec 17, 2022
Product Development
Neoantigens Part III: Picking up the pace
The field ends a busy 4Q22 with Moderna’s highly anticipated, heavily scrutinized data
BioCentury | Nov 29, 2022
Deals
Galbraith’s commitment to cell therapy leads AZ to buyout of Neogene
Shareholders to receive $200M up front, up to $120M more; realize exit just over two years after series A
BioCentury | Nov 1, 2022
Product Development
Neoantigens Part II: cell therapies
An overview of the growing field, company players and emerging data
BioCentury | Jan 12, 2022
Deals
Jan. 11 Quick Takes: Roche cash infusion brings Freenome’s overall haul to $1.1B
Plus: NCI licenses for Neogene, Sana and updates from Allogene-Antion, Illumina bluebird, ONK, Gameto
Items per page:
1 - 10 of 23